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Macrophage Integrin-Mediated, HuR-Dependent Angiogenic Factor Gene Expression
Yasha Modi, Jiange Zhang, Timur Yarovinsky, Mark Collinge, Gautham K. Rao, Yizhun Zhu, Jeffrey R.
Bender, Yale University, New Haven, CT.
Activated macrophages, via the secretion of pro-angiogenic factors, modulate the angiogenic
response to inflammation. Several of these factors, including vascular endothelial growth factor (VEGF),
are encoded by inherently unstable mRNA transcripts containing AU-rich elements (AREs) in their 3’
untranslated region. During stress events, the half-lives of these mRNAs must be prolonged to allow for
significant protein production and an adequate angiogenic response. This laboratory has demonstrated that
engagement of the β2-integrin receptor, LFA-1, leads to stabilization of ARE-bearing mRNAs in T
lymphocytes through a nuclear-to-cytoplasmic translocation of the RNA-binding protein, HuR. Here, we
address whether β2-integrin engagement stabilizes VEGF mRNA in macrophages in vitro and at sites of
angiogenesis via a HuR-dependent mechanism.
To determine whether 2-integrin engagement regulates VEGF mRNA stability, we adhered
primary mouse bone marrow-derived macrophages to ICAM-1 (β2-integrin ligand) for 3 hours. VEGF
mRNA degradation was measured by quantitative RT-PCR after transcriptional inhibition. In the cells
bound to ICAM-1, the VEGF mRNA remained stable, whereas, in non-integrin engaged control cells,
VEGF mRNA degraded to less than 50% of initial levels within 60 minutes. Furthermore, in BMDMs
deficient in HuR expression, VEGF mRNA from integrin-engaged cells degraded to 50% within 60
minutes, thus supporting the essential role of HuR in this stabilization event.
To study inflammatory angiogenesis in vivo, we used a subcutaneous polyvinyl alcohol (PVA)
sponge model to assess differences in wild-type and ―macrophage-specific‖ conditional HuR knockout
(HuRflox/floxLysM-Cre) mice. Flow cytometry analyses of cells extracted from PVA sponges at 1 to 4 weeks
showed equal recruitment of F4/80+ cells in wild-type and HuR knockout mice. Immunofluorescence
staining of excised PVA sponges confirmed equal macrophage recruitment and localization but revealed a
reduction of VEGF production. Preliminary results indicate that formation of CD31+ microvessels in HuR
knockout mice is also decreased.
We conclude that macrophage β2-integrin engagement results in stabilization of VEGF and that
expression of HuR in macrophages is required for neovascular responses. These findings are relevant to
understanding the post-transcriptional regulatory mechanisms of inflammatory angiogenesis.
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Introduction:
The process of small blood vessel formation in adults is called neovascularization
or angiogenesis. This process occurs from pre-existing vessels or from the recruitment of
endothelial progenitor cells (EPCs) from the bone marrow into tissues. Angiogenesis,
responding to a complex set of stimuli, occurs in both physiologic and pathologic
conditions. Embryogenesis and remodeling of the capillary bed in adult skeletal muscle
in response to regular exercise are examples of the former (1). Pathologic conditions that
induce angiogenesis include tumor growth, ischemic injury, and chronic inflammation.
In the setting of cardiovascular disease, such as coronary artery disease, there are
components of both ischemia and inflammation that promote angiogenesis. It has been
previously shown that the extent of coronary artery collateral circulation (angiogenicinduced circulation) is the primary determinant of the extent of necrosis (2). This
collateral development was shown to be mediated by angiogenic growth factors (3, 4),
such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in response to inflammatory and ischemic stimuli (5, 6, 7). Numerous growth
factors and cell types have since been identified to contribute to the complex regulation
of this phenomenon.
VEGF is one of the most extensively studied angiogenic growth factors. Seven
VEGF isoforms (VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F and
placental growth factor) are formed as a result of alternative splicing from a single VEGF
gene. In humans, the abundant isoforms include VEGF121, VEGF165, VEGF189, and
VEGF206, which differ in their molecular mass and in their biological properties, such as
their heparin-binding affinity. VEGF serves as an endothelial cell mitogen stimulating

proliferation, migration and tube formation that is necessary for the development of
neovessels (8). This activity is essential during embryogenesis. The deletion of one
VEGF allele arrests angiogenesis resulting in embryonic lethality (9). Furthermore,
dysregulation of VEGF results in tumor angiogenesis (10) and retinal disease (11).
The expression of VEGF is upregulated in response to hypoxia, oncogenes, and
several cytokines (12). Hypoxia has been the best studied stimulus to VEGF gene
expression with several identified mechanisms (13). Potentiation occurs via increased
transcription, mRNA stability, and at the level of protein translation. The increase in
VEGF transcription is mainly regulated through the hypoxia inducible factor-1 (HIF-1).
HIF-1 is a transcription factor consisting of two subunits. HIF-1α serves as the inducible
component while HIF-1β is constitutively produced (14). Under physiologic conditions,
HIF-1α remains inactive via targeting through proteosomal degradation by hydroxylation.
Under hypoxic conditions, the hydroxylation event is inhibited resulting in salvage of the
HIF-1α subunit. This subunits complexes with the HIF-1β subunit, translocates into the
nucleus and binds to the hypoxia responsive element (HRE) in the 5’ region of the VEGF
gene allowing for transcriptional upregulation (15, 16, 17).
At the level of mRNA stability, in vitro mRNA degradation assays in cell lines
have confirmed that the VEGF mRNA half life is 60 minutes under normoxic conditions.
However, under hypoxic conditions, the half-life of VEGF mRNA increases by 2-3 fold
(7). This mechanism of stability is due to the a RNA-binding protein, HuR, which binds
to the 3’ untranslated region (UTR) of the VEGF mRNA, protecting it from degradation
by endonucleases (18, 19). This method of regulation is the focus of this study and will
be discussed in greater detail below.

Control at the level of protein translation is believed to occur via regulation of the
VEGF mRNA transcript at the internal ribosomal entry site (IRES) as well as by
increased expression of oxygen-regulated protein 150 (ORP 150). The 5’ UTR of VEGF
mRNA contains many IRES, which are sites of attachment for the ribosome. These sites
are thought to provide alternative sites for translational control for VEGF (20).
ORP 150 is believed to be an alternative site for translational control. This
protein is a chaperone required for transport of proteins from the endoplasmic reticulum
to the golgi apparatus. This protein is upregulated in response to hypoxia, which is
believed to result in increased VEGF protein transport and secretion (21).
These mechanisms of VEGF gene expression regulation allude to the complex
role of angiogenic regulation in response to stressors, such as hypoxia. This regulation
occurs in a number of cells that participate in the angiogenic response. Several studies
have identified macrophages as one of the key cell types in regulating the angiogenic
response. Macrophages, playing a large role in innate immune protection, are involved in
anti-bacterial or anti-tumor activity (phagocytosis), antigen presentation, and the
production and release of a variety of regulatory factors including peptides (cytokines),
prostanoids, and enzymes (22, 23). Macrophages originate from bone marrow
progenitors (i.e. monoblasts, promonocytes) and circulate as monocytes (24, 25). Under
physiologic conditions, monocytes circulate in the blood with a 3 day half-life in humans
(26). Under pathologic conditions, there is a significant increase in bone marrow
production, a shorter circulation time, and increased tissue extravasation, causing
macrophage accumulation at pathologic tissue sites (27). In fact, almost any disturbance
in the local milieu, including infection, wound healing, ischemia, malignancy, immune

activation, or normal cell turnover results in recruitment of macrophages to the area (28).
This recruitment from the blood stream to sites of injury is generically referred to as
―macrophage activation‖.
It has been well documented that activated macrophages play a role in modulating
the angiogenic response (29), particularly via the secretion of angiogenic factors,
including VEGF, tumor necrosis factor α (TNF-α), monocyte chemoattract protein 1
(MCP-1), and granulocyte-macrophage colony-stimulating-factor (GM-CSF).
Chemokines secreted during the ischemic response (by resident macrophages and other
inflammatory cell types) recruit monocytes to the affected region, where these monocytes
adhere to the endothelium, transmigrate into the ischemic tissue, differentiate into
macrophages and produce VEGF and other pro-angiogenic substances upon activation.
The recruitment to sites of inflammation or ischemia is a key component of
macrophage activation. Monocyte adhesion receptors engage endothelium adhesion
ligands. Leukocyte glycoproteins, called selectins, allow for reversible cell binding on
endothelium by engaging oligosaccharide ligands on the endothelium (30, 31). This
interaction is not strong enough to anchor the cells against the force of blood flow, which
leads to a series of engagement/ disengagement events that allow the leukocyte to roll on
the endothelium. Furthermore, this engagement is not cytokine driven.
Integrins are adhesion receptors which allow for tighter binding. The two most
studied macrophage integrins are the β2-integrins, Mac-1 (also known as CR3) and
lymphocyte function-associated antigen-1 (LFA-1). LFA-1, a αLβ2 integrin, is a
heterodimeric protein consisting of the subunits CD11a and CD18 (30). As monocytes
approach the hypoxic tissue under the influence of chemokines, LFA-1, which is

expressed on the plasma membranes of monocytes, macrophages, and lymphocytes,
engages its ligand, the intercellular adhesion molecules (ICAMs). This group of ligands
or counter-receptors, consisting mostly of ICAM-1 and ICAM-2, are proteins within the
immunoglobulin superfamily that are expressed by APCs as well as vascular endothelium
(31, 32). This engagement not only allows for strong adhesion and transmigration of the
leukocyte through the endothelium, but also results in LFA-1 activation (33, 34). The
transmembrane signaling cascade that ensues includes multiple second messenger and
kinase activation events, including inositol phosphate (IP3) (35, 36), phospholipase C
(PLC) (37) and protein kinase C (38).
In the activated state, after chemokine induction and LFA-1 engagement,
macrophages produce several pro-inflammatory and pro-angiogenic cytokines, which
have tightly controlled expression profiles. As previously mentioned, these proangiogenic mRNAs are inherently unstable, but upon activation, the half lives of the
transcripts are increased resulting in greater protein production (39). This suggests a
significant posttranscriptional regulatory mechanism for cytokine production. At rest, the
degradation process of these transcripts is rapidly initiated by shortening of the 3’ poly
(A) tails (40). The unifying component of these short-lived cytokines is that the mRNAs
possess a conserved adenine and uridine (AU)-rich element (ARE) in their 3’
untranslated region (UTR), which makes them highly susceptible to rapid degradation by
RNAases after transcription (40). Two studies have identified a specific nonameric
sequence (UUAUUUAUU) responsible for this destabilization (41, 42). Several
regulatory proteins have high binding affinities to RNAs containing these AREs, which
further regulate the half lives of these transcripts. Some ARE-binding proteins

destabilize the transcripts. Examples include AU-rich element RNA-binding protein 1
(AUF1) (43) and KH-type splicing regulatory protein (KSRP) (44). Some ARE-binding
proteins, however, stabilize the transcript. One such protein, HuR, is a member of the Hu
family of RNA binding proteins. This protein is a nucleocytoplasmic protein, located
almost exclusively in the nucleus under rest conditions, but translocates into the
cytoplasm after cellular activation (45). Previous studies have shown that HuR binds to
AREs and stabilizes cytokine transcripts, allowing for greater protein production (46).
Specific to angiogenic transcripts, the Levy groups has shown in a rat myocyte cell line
that HuR binds the AREs in the 3’ UTR of VEGF mRNAs, increasing the half-life of the
transcript 2-3 fold (7). Thus, mRNA stabilization is a crucial regulatory process that
determines the overall production of cytokine and angiogenic substances.
The connection between HuR and the transmembrane signals induced by β2
integrin LFA-1 engagement are of particular importance in understanding mRNA
stabilization. Previous results in T lymphocytes from the Bender lab have shown that
engagement of LFA-1 in human peripheral T cells significantly extends the half-life of
ARE-containing transcripts, including TNF-α, GM-CSM, and Interleukin 3 (IL-3), with
consequent enhanced protein production. Furthermore, LFA-1 engagement is necessary
for the nuclear-to-cytoplasmic translocation of the mRNA-stabilizing protein, HuR. This
redistributed cytoplasmic HuR is capable of binding an AU-rich element sequence in
vitro. Finally, abrogation of HuR levels by use of inhibitory peptides or RNA
interference prevents LFA-1 engagement-mediated stabilization of these mRNA
transcripts in T cells (46). Taken together, these results clearly demonstrate the

connection between LFA-1 engagement and HuR-mediated mRNA stabilization in T
cells.
We hypothesize that the interaction between LFA-1 and HuR is similar in the
macrophage. Once in the cytoplasm, HuR can bind to the ARE sequence of an angiogenic
mRNA transcript, providing the necessary stability to facilitate angiogenic factor
production. Although never studied in the macrophage, the Levy group has previously
shown in various cell lines that HuR modulates VEGF mRNA stability. However, the
role of integrin engagement controlling HuR modulation has never been investigated. It
is our intention to study this connection in the macrophage using VEGF transcript
stability as one of our representative markers for posttranscriptional angiogenic
regulation.
There is little known about the mechanisms regulating angiogenic factor mRNA
stabilization in vivo, and how those mechanisms play roles in dynamic responses to
ischemia and inflammation. In particular, how chemokine stimulated monocyte
recruitment and β2 integrin-mediated cell adhesion/transmigration enhance early
neovascular responses to tissue ischemia, through effects on mRNA stability, is a truly
novel aspect of vascular biology and physiology. This has great relevance in the context
of both peripheral and coronary artery disease, in which ischemic skeletal or cardiac
muscle often remains viable only if there are prominent angiogenic responses.

Hypothesis:
In response to chronic inflammation or tissue ischemia, monocyte/macrophage β2
integrin engagement results in modulation of the mRNA-binding protein HuR, resulting
in stabilization of VEGF transcripts and enhanced angiogenic responses. Macrophagespecific HuR gene deletion results in a diminished angiogenic response.

Specific Aims:
1. To determine whether β2-integrin-induced VEGF mRNA stabilization is HuR
dependent in murine bone marrow derived macrophages (BMDMs).
2. To determine whether β2-integrin-induced VEGF mRNA stabilization is lost in
macrophages obtained from HuR knockout mice.
3. To use the macrophage-specific HuR knockout mice in in vivo angiogenesis assays
using a sponge implantation model.

Methods:
(All work was performed by Yasha S. Modi unless stated otherwise)
Antibodies and Reagents
The following antibodies were used: anti-HuR (3A2) antibody (Santa Cruz, Ca),
anti-p38MAPK (Cell Signaling, MA), phospho-p38MAPK (Cell signaling, MA) FITCconjugated anti-F4/80 (eBioscience, CA), Alexa 648-conjugated anti-F4/80 (eBioscience,
CA), PE-conjugated anti-CD11b (BD Pharmingen, NJ), anti-CD31 (PECAM (BD
Pharmingen, NJ), cyanine-3-conjugated goat anti-mouse antibody (Jackson
Immunoresearch, PA), and IRDye 800 conjugated goat anti-rabbit (Rockland, PA).
Other agents included 5,6-dichloro-1-β-D-ribobenzimidazole (DRB) (Sigma, MO) and
DAPI (Sigma, MO).
The constituents of ―LFA-1 activation buffer‖ include: 100 mM Tris. HCL, pH
7.4, 150 mM NaCl, 2 mM MnCl2, 20 mM MgCl2, D-glucose 5 mM, and 1.5 % BSA.
The constituents of ―fully supplemented‖ RPMI media include: 10% fetal bovine serum,
2 mM glutamine, 25 mM HEPES, 1.75 µL 2-Mercaptoethanol, 1 mM Sodium Pyruvate,
and 100 U/ml each of penicillin G and streptomycin. ―L Cell supernatant‖ is supernatant
from ―fully supplemented media‖ 12 days after plating (10 days post confluence) of L929
cells, a fibroblast tumor line. 2:1 RPMI:L Cell or ―macrophage growth media‖ signifies
two parts fully supplemented RPMI and 1 part L Cell supernatant.
Bone Marrow Extraction and Macrophage Isolation
Macrophages were extracted and cultured from C57BL/6 wild type (HuRflox/flox)
or macrophage-specific HuR knockout mice (HuRflox/floxlysMcre). Mice were first
anesthetized by placement into an isoflurane chamber and euthanized by cervical

dislocation. Femurs and tibias were isolated, washed (1x 70% ethanol, 3x in CMF-PBS),
and ground with a mortar and pestle in fully-supplemented RPMI media. Bone
homogenate was then filtered through a 70 µm filter and centrifuged at 1500 RPM at
room temperature. Cells were resuspended in RBC lysis buffer (0.15 mM NH4CL, 1 mM
KHCO3, 0.1 mM EDTA) in order to lyse red blood cells. Cells were then washed once,
counted, and plated in ―macrophage-growth media‖ at a concentration of 4 million cells/7
mL media in a 10 cm non-tissue culture petri dish. Cells were left in this media for 7
days, with addition of 4 ml fresh media on day 4 (47). The ―macrophage-growth media‖
consists of monocyte colony stimulating factor (M-CSF) enriched media + fully
supplemented RPMI in a 1:2 ratio. M-CSF enriched media was generated by collection
of supernatant from a fibroblast tumor line 10 days after confluence was achieved (L929
cell line, ―L cell media‖).
VEGF mRNA Decay Assay
Petri dishes were coated with 100ng/ml recombinant murine ICAM-1/Fc chimera
protein (R&D Systems, MN) in 2% dialyzed FBS/CMF-PBS overnight at 4˚C. Control
plates were coated with an Fc conjugate, Goat-α-Human IgG, Fc fragment (Jackson
Immunoresearch, PA), and blocked overnight in 2% dialyzed FBS/CMF-PBS at 4˚C.
Murine bone-marrow derived macrophages (4x106/sample) in ―LFA-1 activation buffer‖
were allowed to adhere to ICAM-1 coated plates or the Fc conjugate control plates.
―LFA-1 activation buffer‖ (100 mM Tris. HCL, pH 7.4, 150 mM NaCl, 2 mM MnCl2, 20
mM MgCl2, D-glucose 5 mM, and 1.5 % BSA) is a cation-based solution that allows
cations, particularly manganese, to bind to the metal ion-dependent adhesion site
(MIDAS) on the ligand-binding domain of LFA-1 (48). This binding induces an

allosteric transition to a high affinity state for its ligand (ICAM-1, in this experiment),
aiding in cell adhesion without cell activation. After 30 minutes of cell adhesion, the
activation buffer was aspirated and replaced with fully supplemented RPMI for 2.5 hours.
mRNA synthesis was inhibited after a total of 3 hrs incubation (0.5 hrs in activation
buffer, 2.5 hours in RPMI) by the addition of 25 µM of the RNA polymerase II inhibitor
5,6-dichloro-1-β-D-ribobenzimidazole (DRB) (Sigma, MO). Non-adherent cells were
aspirated and adherent cells were lysed in RLT lysis buffer (Qiagen, Ca) containing βmercaptoethanol (2-ME) at various time points post DRB addition for RNA isolation.
RNA was isolated with the Qiagen RNeasy kit (Qiagen, Ca). cDNA was generated from
1 µg of total RNA with iScript (Bio-rad, CA). Analysis was performed via quantitative
real-time PCR (Opticon 2 sytem, MJ Research, MA) using a SYBR Green PCR kit
(Qiagen, Ca). Murine VEGF mRNA levels were normalized against beta-actin with
expression levels relative to time 0 when transcription was inhibited. The sequence of
the VEGF primers used for RT-PCR was: Forward primer:
GGAGATCCTTCGAGGAGCACTT, Reverse primer:
GGCGATTTAGCAGCAGATATAAGAA. The sequence of the housekeeping beta actin
primers used for RT-PCR was: Forward primer: GTGGGCCGCTCTAGGCACCAA,
Reverse primer: TGGCTTTAGGGTTCAGGGGG. The primers were designed by
Gautham Rao and synthesized by the Keck Biotechnology resource facility at Yale.
HuR Translocation and Immunofluorescence
Sterile glass coverslips were coated with 100ng/ml murine ICAM-1/Fc chimera
protein in 2% dialyzed FBS/CMF-PBS overnight at 4˚C. Control coverslips were coated
with an Fc conjugate (Goat-α-Human IgG, Fc fragment) and blocked overnight in 2%

dialyzed FBS/CMF-PBS at 4˚C. Murine bone-marrow derived macrophages
(106/sample), in ―LFA-1 activation buffer‖ were allowed to adhere to ICAM-1 coated
plates or the Fc conjugate control plates for 45 minutes. Cells were then fixed with 4%
paraformaldehyde and permeabilized with 0.1 % triton X-100. Cells were blocked with
5% goat serum for 2 hours at room temperature and then incubated in anti-HuR antibody
(1:500) overnight at 4˚C. Cells were then washed and incubated with cyanine 3conjugated goat anti-mouse antibody (1:1000) for 1 hour at room temperature. Cells
were then counterstained with 0.005 % 4',6-diamidino-2-phenylindole (DAPI) for nuclear
staining.
p38MAPK Phosphorylation Assay
Petri dishes were coated with 100ng/ml murine ICAM-1/Fc chimera protein in
2% dialyzed FBS/CMF-PBS overnight at 4˚C. Control plates were coated with an Fc
conjugate (Goat-α-Human IgG, Fc fragment). Murine bone-marrow derived
macrophages (4x106/sample), in ―LFA-1 activation buffer‖ were allowed to adhere to
ICAM-1 coated plates or the Fc conjugate control plates for 5, 10, 15, and 20 minutes.
Cells were subsequently lysed in RIPA cell lysis buffer (1% Sodium Deoxycholate, 0.1%
SDS, 1% NP-40, and protease inhibitor in PBS). Total protein was run on a 10% SDSPAGE gel, transferred to nitrocellulose membrane, and immunoblotted with antiphospho-p38MAPK (1:1000), and anti-p38MAPK (1:1000, loading control). Of note, it
is accepted practice to quantitatively measure p38 activation with antibodies against
phosphorylated p38 MAPK. After 3x washing, the membrane was probed with IRDye
conjugated goat-anti-rabbit (1:10000) and visualized using an Odyssey Imaging System
(LI-COR Biosciences, Nebraska).

Overview of Development of HuRflox/floxLysMcre Mouse (Macrophage-Specific HuR
Knockout Out)
The development of the HuRflox/floxLysMcre started in 2004 and was designed and
developed by Mark Collinge, a former senior researcher in the Bender laboratory. All
genetic modifications were performed on a C57BL/6 background. Briefly, exon 2 of the
HuR gene was targeted and via standard gene targeting (49, 50), the gene was floxed by
―loxP‖ cre recombinase recognition sites. By crossing mice, both alleles of the HuR gene
were floxed, providing the designation HuRflox/flox. Confirmation of homozygous floxing
was determined by genotype analysis. This mouse was then crossed with a genetically
engineered mouse expressing cre recombinase under the control of the LysM promoter
(Jackson Laboratories, ME). The LysM promoter is found exclusively in macrophages
and neutrophils, and thus the LysM driven cre recombination only results in HuR
excision in macrophages and neutrophils. After multiple generations of crossing, the lab
generated a HuRflox/floxLysMcre mouse. This mouse was genotypically confirmed to be
homozygous for LysM cre expression. Of note, the acquired mouse expressing cre
recombinase, has the recombinase gene genetically targeted in place of the lysozyme M
gene. That is, the HuRflox/floxLysMcre is in fact a double knockout in macrophages and
neutrophils, deficient in HuR and LysM cre. This decision was consciously made as
lysozyme M does not play a known role in inflammatory and ischemia-induced
angiogenesis.
Surgical Model of Chronic Inflammation: Polyvinyl Alcohol Sponge Implantation
& Harvesting

Implantation: Polyvinyl Alcohol (PVA) Sponges (Ultracell Medical
Technologies, Inc., CT) were cut into 1mm x 2mm sections in a sterile fashion. Mice
were anesthetized using 10% ketamine (stock: 100 mg/mL), 5% xylazine (stock: 20
mg/mL) saline based solution. The dorsum of the animal was shaved and cleaned with
iodine/alcohol. A 1.25 cm incision was made along the spine from mid-back to upper
back. The skin was retracted and lateral blunt dissections were made subcutaneously 1.5
cm away from the incision site to create right and left subcutaneous pockets. A sponge
section (1 mm x 2 mm) was inserted into each subcutaneous pocket and the skin was
stapled shut for 1 week.
Explantation: Mice with PVA sponge implants were euthanized and the dorsum
overlaying the implant site was shaved. The original incisions were reopened and
sponges were extracted along with adherent skin to preserve orientation. For
immunohistochemistry, sponges with adherent skin were fixed in a formalin-free zinc
fixative solution (BD Pharmingen, NJ), embedded in paraffin, and sectioned into 5 µm
sections. Paraffin embedding and sectioning was performed by the Yale Pathology
Department. Immunohistochemistry staining using anti-CD31 antibody (1:50) was
performed (secondary antibody: biotinylated anti-rat, Vector Labs, California). For RNA
isolation, sponges without adherent skin were homogenized using a tissue homogenizer
in lysis buffer. For flow cytometry, sponges without adherent skin were minced using a
razor blade and cells were extracted by type I collagenase (274 U/ml) (Worthington, NJ)
treatment. RBCs were subsequently lysed using the RBC lysis buffer (described above).
Microarray Analysis:

The microarray analysis was developed to assess gene expression profile
differences between WT and KO bone marrow derived macrophages (BMDMs) adhered
and non-adhered to ICAM-1. Groups included ―WT No Treatment‖, ―HuR KO No
Treatment‖, ―WT ICAM‖, ―KO ICAM‖, where ―WT‖ denotes BMDM from HuRflox/flox
mice and ―KO‖ denotes HuRflox/floxLysMcre mice. Furthermore ―No Treatment‖ implies
cells harvested and not adhered, while ―ICAM‖ denotes macrophages bound to ICAM-1
(LFA-1 engaged).
Bone marrow derived macrophages (BMDMs) from HuRflox/flox (WT) mice and
HuRflox/floxLysMcre (KO) mice were cultured in triplicate (3 WT mice, 3 KO mice on
different days) in order to account for biological variability. The ―no treatment‖ control
samples were pooled from the three independent WT and KO macrophage cultures upon
harvesting, comprising the ―WT No Treatment‖ and ―KO No Treatment‖ categories,
respectively. After compiling the total macrophages from each sample, there were a total
of 5 million cells for the ―WT No Treatment‖ group and ―KO No Treatment group‖ (1.67
million BMDMs from each WT and KO culture x 3 cultures).
To determine the effect of macrophage adhesion to ICAM-1, the following
experiment was repeated 3 times in identical fashion on sequential days: Petri dishes
were coated with 100ng/ml murine ICAM-1/Fc chimera protein in 2% dialyzed
FBS/CMF-PBS overnight at 4˚C. Control plates were coated with an Fc conjugate (Goatα-Human IgG, Fc fragment) and blocked overnight in 2% dialyzed FBS/CMF-PBS at
4˚C. Murine BMDMs (5x106/sample) in ―LFA-1 activation buffer‖ were allowed to
adhere to ICAM-1 coated plates or the Fc conjugate control plates. After 30 minutes of
cell adhesion, the activation buffer was aspirated and replaced with fully supplemented

RPMI for 2.5 hours. At three hours, non-adherent cells were aspirated and adherent cells
were lysed (in RLT lysis buffer + 2-ME) for RNA isolation. RNA was isolated with the
Qiagen RNeasy kit. Subsequent RNA samples were sent to the Keck Biotechnology
resource facility at Yale. A total of 8 samples were given to them for hybridization:
Compiled ―WT No Treatment‖, compiled ―KO No Treatment‖, 3 ―WT ICAM‖ samples,
and 3 ―KO ICAM‖ samples.
All subsequent steps to analysis were performed by the Keck Biotechnology
facility. Briefly, these steps involve converting total RNA to amplified, labeled cRNA
prior to hybridization. First, the total RNA is reverse transcribed to cDNA via use of the
poly (A) RNA present. Single stranded cDNA is then converted into double stranded
cDNA and purified (Illumina TotalPrep RNA Amplification Kit, CA). This is followed
by an overnight in vitro transcription (IVT) reaction in the presence of biotinylated UTP
and CTP to generate biotin-labeled cRNA. The cRNA then undergoes a purification step
using the same Amplification Kit. 1.5 µg of cRNA from each sample (8 total samples) is
then hybridized to the MouseRef-8 v1.1 Expression BeadChip (Illumina, CA).

Results:
Bone marrow extraction yields a 93 to 98.5% pure population of F4/80+, CD11b+
cells.
Prior to performing in vitro studies with cultured BMDMs, it was important to
check the efficiency and purity of BMDM cultured via our isolation technique. From
C57BL/6 mice, tibias and femurs were isolated. Bone marrow cells were extracted and
cultured in ―macrophage growth media‖ for 7 days. On day 7, the non-adherent cells
were removed and the adherent cells were collected for analysis. Cells were double
stained for F4/80 (FITC) and CD11b (PE), two standard macrophage markers. The
results are illustrated in Figure 1. After gating on the live population of cells, 94% of the
cells are double positive, indicating 6% non-macrophage cells. Similar experiments
confirmed 93.5 to 98.4% double-positive macrophages (data not shown). These results
demonstrate that the macrophage isolation, differentiation, and expansion protocol is
yielding relatively pure numbers of macrophages.
LFA-1 engagement induces VEGF mRNA stabilization
Previous studies from the Bender lab have demonstrated the role of LFA-1
engagement-mediated mRNA stabilization after engagement to ICAM-1, a physiologic
ligand of LFA-1, in T cells. As macrophages play a large role in the angiogenic
response, our first aim was to assess whether LFA-1 engagement promotes VEGF mRNA
stabilization. BMDMs were harvested at day 7 of differentiation and were used to
perform an in vitro mRNA decay assay (as described in the ―Methods‖ section). To
measure the half life of BMDM transcripts present at the time of transcriptional arrest,
adherent cells were lysed at 0, 30, and 60 minutes post DRB (RNA polymerase II

inhibitor) addition. The transcript levels of VEGF were compared to the stable,
housekeeping mRNA encoding beta actin at each time point. The results are illustrated in
Figure 2. The x-axis represents time after DRB addition while the y-axis demonstrates
normalized VEGF mRNA as a % of time 0 (DRB addition). When BMDMs are not
LFA-1 engaged (plated on Fc control plates), their VEGF mRNA transcripts decays to 50
% (t ½) within 30 minutes. However, when macrophages are bound to ICAM-1 (LFA-1
engaged), their transcript levels remain constant through 60 minutes post-transcriptional
arrest. These results demonstrate that LFA-1 engagement by ICAM-1 leads to
stabilization of the mRNA transcript encoding the pro-angiogenic cytokine, VEGF.
LFA-1 engagement results in HuR nuclear-to-cytoplasmic translocation
VEGF mRNA transcripts contain destabilizing AREs in their 3’-UTRs (7). Since
HuR has been shown to bind mRNA AREs and prevent degradation of those transcripts,
and since LFA-1 engagement induces VEGF transcript stability, we hypothesized that
LFA-1 engagement stabilizes transcripts via HuR. Previous studies from the Bender lab
have shown that LFA-1 engagement results in HuR nuclear-to-cytoplasmic translocation
and subsequent mRNA binding to class II AREs in T cells (46). Here we assess whether
LFA-1 engagement causes HuR translocation in murine BMDMs. Mature murine
BMDMs underwent 45 minutes of an in vitro translocation assay (see ―Methods‖
section), then were fixed, permeablized and stained with anti-HuR antibody (with DAPI
counter-stain for nuclear definition). Immunofluorescence images are depicted in Figure
3. After 45 minutes of adhesion to ICAM-1, a substantial amount of HuR has
translocated out of the nucleus, seen clearly in the overlay image. In the presence of
LFA-1 activation buffer with cells adhered to control coverslips (Fc conjugate antibody),

HuR remains exclusively nuclear. This demonstrates that BMDM LFA-1 engagement
results in HuR nuclear-to-cytoplasmic translocation, which is consistent with the
hypothesis that LFA-1 engagement stabilizes transcripts via HuR.
Macrophage LFA-1 engagement activates the p38 MAPK pathway
After demonstrating with murine BMDMs that LFA-1 engagement results in HuR
translocation and stabilization of VEGF mRNA transcripts, we sought to define the
signaling molecules in this rapid, posttranslational event. Previous data from the Bender
lab in T cells has shown that LFA-1 engagement with resultant HuR translocation is
mediated via Rho family GTPase Rac (Rac 1 and Rac 2). p38 MAPK is a downstream
Rac effector that has been linked to modulation of mRNA stability. Here we demonstrate
the activation of p38 MAPK after LFA-1 engagement in murine BMDMs. Mature
macrophages were used for an in vitro p38 MAPK phosphorylation assay (see ―Methods‖
section). Time points were 5, 10, 15, and 20 minutes. An immunoblot was prepared and
probed for activation-specific p38 phosphorylation. Loading controls were determined
by probing for total p38. The immunoblot is shown in Figure 4. Within 5 minutes of
BMDM engagement to ICAM-1, there is a substantial induction (greater than 6-fold) of
phosphorylation (activation), which persists throughout the 25 minute time course.
Preliminary experiments have recently shown that the p38 inhibitor SB203580 blocks
adhesion-induced mRNA stabilization (not shown). Together, these data demonstrate
that LFA-1 stimulated p38 activation is required for induced mRNA stabilization.
The HuRflox/floxLysMcre (HuR, macrophage specific knockout) mouse yields
inconsistent knockdown of HuR

The HuRflox/floxLysMcre mouse was developed by a senior researcher (Mark
Collinge) in the Bender laboratory (Figure 5). Briefly, exon 2 of the HuR gene was
genetically targeted by ―loxP‖ cre recombinase recognition sites, producing a
homozygous (both alleles ―floxed‖) HuRflox/flox mouse. This mouse was subsequently
crossed with a genetically engineered mouse expressing cre recombinase under the
control of the LysM promoter. The LysM promoter is active exclusively in macrophages
and neutrophils, and thus the LysM promoter driven Cre recombination event results in
HuR excision only in macrophages and neutrophils. The immunoblot in figure 6
confirms the specificity of the HuRflox/floxLysMcre knockout mouse (figure courtesy of
Mark Collinge). In immunoblot A, HuR is absent in the HuRflox/floxLysMcre bonemarrow derived macrophages (KO) but present in the HuRflox/flox macrophages (WT).
When isolating the splenic lymphocytes (immunoblot B) from the same mice, it is
evident that the HuR levels are present and equal. Additional immunoblots using extracts
from BMDMs isolated from different mice were performed. Figure 7 illustrates the
variable knockdown of HuR protein levels in BMDMs from 3 WT and 3 KO mice.
Comparing WT 1 vs. KO 1, the knockdown of HuR is approximately 95%. However,
when comparing WT 2 vs. KO 2, the knockdown of HuR is approximately 53%. This
variability in knockdown using the lysozyme M promoter in a cre-lox system has been
previously described (51). This particular study, using the LysMcre system for cellspecific conditional knockdown has demonstrated a deletion efficiency of 83-98% in
mature macrophages. The knockdown efficiency in neutrophils in that study was
significantly greater, approaching 100%. The variability in our system is greater than has
been previously described (53-95% in our knockdown versus 83-98% in the Clausen

group knockdown). Similar variation can be observed when assessing the transcript
levels of HuR (Figure 8). To ensure the biological variability inherent to the system,
technical errors in genotyping were ruled out and all mice were re-confirmed to have the
HuRflox/flox (WT) and HuRflox/floxLysMcre (KO) genotype. Reasons for the potential
variability in HuR excision may include insufficient or untimely expression of Cre
recombinase. Little is known about the control of the Lysozyme M promoter which is
driving cre recombinase expression. Alternatively, there may be inadequate excision at
the loxP recognition sites. Chromatin structure may prevent the cre recombinase from
recognizing or binding to the loxP sites, resulting in incomplete excision. Finally, as the
BMDM colonies in which these cells are taken from are 93-98% pure macrophages, the
other cells (non-macrophages but expressing HuR) may explain the variable levels of
HuR present within the immunoblot. Further analysis is underway to identify the
significant variability in the LysMcre system.
FACS analysis of bone-marrow derived macrophages and monocytes confirms a
variable knockdown of HuR in the HuRflox/floxLysMcre mouse
To determine whether HuR found in HuRflox/floxLysMcre cells is expressed in
macrophages or contaminating cells, we used intracellular staining for HuR followed by
FACS analysis. BMDMs were harvested on day 7 after culture in macrophage growth
media. In order to acquire peripheral blood monocytes, peripheral blood was drawn from
WT and KO mice via retrobulbar bleeding. BMDMs and monocytes were surface costained with Alexa 647-conjugated F4/80 (1:200) and PE-conjugated CD11b (1:400).
Intracellular HuR staining was achieved by permeabilizing the cells in a 0.2% saponin
wash and staining with Anti-HuR (3A2) antibody conjugated to a zenon alexa 488 tag

(Invitrogen). Single color controls and isotype controls to anti-HuR antibody (mouse
IgG1 isotype control) were also prepared. HuR expression levels from WT and KO
BMDMs are illustrated in Figure 9. After double-gating for CD11b+, F4/80+ cells, HuR
expression levels (via a histogram) may be assessed on the macrophage population. The
shift in the WT HuR stained curve compared to the KO HuR stained curve illustrates
differential expression levels of HuR. As the KO curve almost overlaps the isotype
control, it is apparent that the majority (but not all) of HuR is absent. Complete
knockdown would be represented by absolute overlap of the KO stained curve with the
isotype curve. In order to confirm the presence of HuR in the CD11b+, F4/80+ cell
population, a technique of ―back-gating‖ was used. When gating only the HuR positive
cells from the KO sample (difference between KO HuR and KO isotype histogram), a
small percentage of these HuR gated cells are CD11b+, F4/80+ macrophages (Figure 10).
This result provides further evidence that HuRflox/floxLysMcre (KO) macrophages are
expressing low levels of HuR. That is, the impurity of the BMDM cultures (2-7% nonmacrophages) cannot fully explain the variable levels of HuR expression in the
HuRflox/floxLysMcre macrophages.
HuR expression levels from WT and KO blood monocytes are illustrated in
Figure 11. As described above, after double-gating for CD11b+, F4/80+ cells, HuR
expression levels may be assessed on the monocyte population. Compared to BMDMs,
the shift in the WT HuR-positive curve relative to the isotype control is substantially
smaller. This may be the result of incomplete staining or may indicate that blood
monocytes express less HuR than BMDMs. Furthermore, blood monocytes from
HuRflox/floxLysMcre (KO) mice showed more residual HuR. This recapitulates the

question of variable and insufficient cre recombinase expression under the control of the
LysM promoter. Although unproven, it is possible that differentiation from monocyte to
activated macrophage may alter the activity of the LysM promoter along with cre
recombinase expression. Of note, when assessing HuR levels in the CD11b+, F4/80quadrant, which is representative of granulocytes (and NK cells), the expression of HuR
from the KO mouse is almost completely absent (overlaps the isotype control). This is
consistent with the findings of the Forster group who described the efficiency of deletion
in neutrophils approaching 100% (51).
After discovering that both BMDMs and monocytes from the HuRflox/floxLysMcre
mouse had variable levels of HuR expression, prior screening was required for all
subsequent experiments to establish the level of knockdown. For all in vitro experiments,
mature BMDMs were screened via intracellular HuR staining and assessed by FACS to
ensure at least 90% knockdown. If knockdown was less efficient than this, the cells were
not used for experimentation. For all in vivo experiments, blood monocytes (acquired via
retrobulbar bleed) were screened via intracellular HuR staining and assessed by FACS to
ensure at least 75% knockdown. Mice were allowed to reconstitute their cell counts after
bleeding for one week prior to surgical implantation/manipulation. The threshold for
acceptance was lower when assessing blood monocytes to account for incomplete
intracellular HuR staining.
LFA-1 engagement induces VEGF mRNA stabilization in WT but not in KO
BMDMs
As described above, LFA-1 engagement by ICAM-1 leads to stabilization of
mRNA transcripts encoding the pro-angiogenic cytokine, VEGF. The mechanism of

LFA-1 engagement resulting in VEGF mRNA stabilization is believed to be HuRdependent. In order to confirm this hypothesis, an identical in vitro mRNA stabilization
assay was performed using BMDMs from HuRflox/floxLysMcre (KO) mice and HuRflox/flox
(WT) mice. The results are illustrated in Figure 12. Consistent with previous results,
LFA-1 engaged BMDMs from WT mice demonstrated stability of the VEGF mRNA
transcript through 60 minutes post-transcription arrest. However, VEGF mRNA
transcripts from LFA-1 engaged KO BMDMs decayed to its half life by 60 minutes.
These results indeed demonstrate that VEGF mRNA stabilization after β2 integrin
engagement is HuR-dependent.
LFA-1-induced VEGF protein levels is decreased in KO macrophages.
After establishing the necessity of HuR for VEGF mRNA stability and
confirming the labile nature of KO VEGF mRNA transcripts in BMDMs, we
hypothesized that VEGF protein levels would be greater in WT macrophages compared
to KO macrophages after LFA-1 engagement (as a direct result of increased mRNA
stability). WT and KO BMDMs in LFA-1 activation buffer were adhered to ICAM-1coated or Fc conjugate-coated plates for 30 minutes, then cultured in fully supplemented
RPMI media (without L Cell supplementation) for an additional 23.5 hours. After 24
hours, supernatant was collected for evaluation of VEGF protein levels and the adherent
cells were collected to confirm at least 90% knockdown of HuR protein expression via
western blot (figure not shown). VEGF ELISA results are illustrated in Figure 13. There
is a modest increase (~30%) in VEGF protein obtained from ICAM-bound WT BMDM
supernatants, relative to the non-integrin engaged control (WT ICAM vs. WT NO
ICAM). This integrin-induced augmentation in VEGF protein secretion is lost in the KO

BMDMs (KO ICAM vs. KO NO ICAM). Furthermore, there is a large reduction in
baseline VEGF secretion in the KO cells (WT NO ICAM vs. KO NO ICAM),
demonstrating the role for HuR in both basal and integrin-induced VEGF production.
This is not surprising given the documented importance of HuR in VEGF mRNA
stability.
Polyvinyl Alcohol (PVA) sponge implants from HuRflox/floxLysMcre (KO) mice have
substantially decreased levels of VEGF mRNA at 2 weeks post-implantation.
In vitro BMDM data confirmed that LFA-1 engagement results in VEGF mRNA
stabilization. Via the use of HuRflox/floxLysMcre (KO) mouse macrophages, this
stabilization was determined to be HuR-dependent. To assess the importance of this
phenomenon, an in vivo model of chronic inflammation was used. The polyvinyl alcohol
sponge implantation model was used because it induces a well-established chronic
inflammatory response comprised of significant macrophage recruitment and obvious
angiogenesis (52). Approximately 60% of the cells isolated from a sponge after 6 weeks
(via FACS analysis) are macrophages (F4/80+, CD11b+) (figure not shown).
Furthermore, recruitment of macrophages to sites of inflammation requires LFA-1
engagement. Of note, several presumptions were made regarding this surgical model.
First, the cells infiltrating the sponges are mostly macrophages that have been LFA-1
engaged and activated. Second, the neovascularization event is driven by macrophages
and is VEGF-dependent.
Sterile PVA sponges were placed in surgically constructed subcutaneous pockets
into the dorsum of the WT and KO mice. At various time points (3 days, 1, 2, 3, and 4
weeks), the mice were euthanized and the sponges were explanted. For RNA isolation,

the skin was detached from the sponge. Murine VEGF mRNA levels were normalized
against beta actin. The results are illustrated in Figure 14. The VEGF mRNA levels
obtained from sponges implanted in WT mice were nine-fold greater than that obtained
from sponges implanted in KO mice at 2 weeks. This trend persisted through 3 and 4
weeks but was not as dramatic due to significantly decreased VEGF mRNA expression
after 2 weeks. These results provide the first evidence that differences in WT and KO
VEGF mRNA, likely the result of impaired mRNA stabilization in HuR-deficient
macrophages, can be recapitulated in vivo.
Recruitment of F4/80+, CD11B+ macrophages to the PVA sponge in WT and KO
mice are identical.
Before drawing conclusions about reduced KO macrophage VEGF production in
this model, it was important to determine equal macrophage localization in sponges
implanted in WT and KO mice. That is, any differences in VEGF levels or consequent
angiogenesis must be attributed to a defect in macrophage factor production, and not
attributed to varying levels of macrophages within the sponge. The critical time points
for assessing macrophage recruitment were chosen to correspond to maximal VEGF
production and neovascularization (2, 3, and 4 week post-implantation). As described
above, PVA sponges were implanted subcutaneously over the dorsum of WT and KO
mice. Sponges were explanted at 2, 3, and 4 weeks post-implantation and cells were
extracted via Collagenase Type I digestion. RBCs were subsequently lysed and cells
were double stained for FACS analysis with murine alexa-647 conjugated anti-F4/80
antibody and murine PE-conjugated anti-CD11b antibody. Figure 15 illustrates equal
macrophage recruitment from sponges implanted in WT and KO mice at 3 and 4 weeks.

Similar results were obtained at 2 weeks (figure not shown). Based on cell counts before
FACs staining, absolute numbers of F4/80+, CD11b+ cells can be generated, with
approximately 5 x 105 macrophages obtained from 3 week sponges and 3.5-4 x 105
macrophages from 4 week sponges. These findings indicate that the varying levels of
VEGF mRNA are not due to differences in macrophage recruitment. Rather, these
differences are due to biologic differences between WT and KO recruited cells.
There is only a modest reduction of CD31+ vessels in sponges from KO mice
compared to sponges from WT mice.
After observing significant differences in VEGF expression levels between the
WT and KO mouse at 2, 3, and 4 weeks post-implantation, it was hypothesized that there
would be decreased neovessels in the KO mouse compared to the WT mouse. Sponges
and adherent skin were explanted at 2, 3, and 4 weeks post-implantation and fixed,
paraffin embedded and sectioned. PECAM (CD31) immunohistochemical staining was
performed (Figure 16). The arrows indicate sponge neovessel. The quantified results for
2 week and 4 week WT and KO sponges are illustrated in Figure 17A. The results for a
repeat experiment on 3 week and 4 week WT and KO sponges are illustrated in Figure
17B. All vessels were manually counted by two people who were blinded to the sample.
The first figure represents an average number of CD31+ vessels in 25 fields of view
under high magnification, while the second analysis represents all the CD31+ vessels
present in each sponge. Numbers represent an average of the two counts. Taken
together, these results indicate that there is a reduction in neovessel formation at 3 and 4
weeks in the KO-mouse derived sponges compared to the sponges from the WT mouse
but that the reduction is only modest.

300 genes are upregulated in both WT and KO BMDMs upon adhesion to ICAM-1
The microarray analysis was the first discovery study by our lab looking to assess
gene expression differences between WT and KO BMDMs adhered and non-adhered to
ICAM-1. Groups included ―WT No Treatment‖, ―HuR KO No Treatment‖, ―WT
ICAM‖, ―KO ICAM‖, where ―WT‖ denotes BMDM from HuRfl/fl mice and ―KO‖
denotes HuRfl/flLysMcre mice. Furthermore, ―No Treatment‖ denotes cells harvested and
not adhered, while ―ICAM‖ denotes macrophages bound to ICAM-1. Time of adhesion
was arbitrarily chosen as 3 hours. With these four conditions, three key questions may be
answered. First, expression profiles upon engagement to ICAM-1 may be assessed; this
is a HuR independent finding and would not vary between WT and KO BMDMs.
Second, comparing the unbound (―No Tx‖) WT and KO BMDMs, baseline (un-adhered)
expression profile differences that are dependent on HuR levels may be assessed.
Finally, using all four conditions, expression profile differences may be determined that
are both ICAM dependent (increased /decreased expression on adherence to ICAM-1)
and HuR dependent (increased/decreased expression in BMDMS from KO mice).
Staying consistent with our hypothesis that ICAM-1 adherence leads to a stabilization of
transcripts (therefore higher mRNA levels) and that HuR is required for this stabilization,
our analysis focused mainly on genes upregulated after adhesion to ICAM-1 and on
genes downregulated in BMDMs acquired from KO mice.
After completion of the microarray experiment, a total of 8 RNA samples were
given to the Keck biotechnology facility for microarray hybridization: Compiled ―WT
No Treatment‖, compiled ―KO No Treatment‖, 3 ―WT ICAM‖ samples, and 3 ―KO
ICAM‖ samples. All analysis was performed using the Beadstudio data analysis software

(Illumina, CA). The first analysis compared genes with statistically significant
differences between ICAM-bound versus non-ICAM bound samples, using WT No TX
as the reference group. That is, all listed genes show a significant induction on ICAM
over untreated samples. Statistical significance was determined by use of a ―differential
(Diff) score‖. The Diff score is a log transformation of the p-value. The formula is:
Diffscore = 10 x sgn(μref-μcond) x log10(p). The translation is as follows: for a p-value
of 0.05, the Diff Score = ± 13, for a p-value of 0.01, the Diff Score = ±20, for a p-value
of 0.001, the Diff Score = ± 30. This transformation is useful because it provides
directionality to the p-value based on the difference between the average signal in the
reference group (WT No Tx in this analysis) vs. the comparison group. This study
utilized a Diff score of +/- 13 to establish significance. In order to identify genes that
have LFA-1 dependent (bound to ICAM-1) gene expression profiles, an ―AND/OR tree‖
was used to filter genes that conform to this profile. With the reference group set to ―Wt
No Tx‖, branch 1 of the tree was as follows: KO, diff score > 13, KO, diff score <-13.
Branch 2 was: KO, p-value < 0.01, WT No Tx, p-value < 0.01. This filter produced
5924 genes, of which 300 genes had positive Diff scores greater than or equal to 13
comparing WT ICAM bound to the reference group. That is, there was a significant
induction on ICAM relative to the ―WT No Tx‖ sample. Of these genes, several
chemokine genes had significant induction patterns on ICAM-1. These chemokines were
selected for validation via RT-PCR. Primers were designed for CCL2, CCL3, CCL4,
CCL5, and CCL7. An identical experiment was conducted using BMDMs from a WT
and KO mouse. The results are illustrated in Figure 18. For all chemokines analyzed,
there was a significant induction on ICAM-1 relative to the ―WT No Tx‖ group. The

patterns of gene expression between WT ICAM and KO ICAM were equal or only
slightly varied, however, suggesting HuR independence.
The second analysis was designed to assess genes with statistically significant
differences between the bound ―WT ICAM‖ and ―KO ICAM‖ samples. This study was
designed to address not only the HuR dependent genes, but also the HuR and LFA-1
dependent genes. The reference group was set to ―KO 3 ICAM‖. The ―KO ICAM‖
groups were run in triplicate and this sample had the largest knockdown of HuR
expression levels (90%) on retrospective analysis via RT-PCR. Once again, Diff scores
of +/- 13 were set as our cutoff for achieving statistical significance. In order to identify
genes that are HuR dependent, an ―AND/OR tree‖ was used to filter genes that conform
to this profile. An ―AND/OR tree‖ was developed. Branch 1: WT 3, diff score > 13,
WT 3, diff score <-13, and Branch 2: WT 3 detection p value < .01, KO 3 detection p
value < .01. The total number of genes displayed that fit this filter was 1045. When
assessing genes with + diff scores of 13 or more (significant induction on WT ICAM 3 or
KO ICAM 3), 29 genes fit this pattern (Table). That is, there is a HuR dependent
component to each of these genes. Furthermore, 5 of these genes appear to be both
dependent on HuR and induced on ICAM-1. These genes are Caveolin 1 (Cav 1), TAP
Binding Protein (TAPBP), Moesin (Msn), G protein-coupled receptor 84 (GPR84), and
RNA binding protein gene with multiple splicing (RBPMS) (Figure 19). Interestingly,
none of the inflammatory or angiogenic cytokines that are known to be HuR-dependent
(i.e. TNF-α) appeared on this list. As for the five genes that have emerged from this list,
the connection between HuR or LFA-1 has not been made. Furthermore, these findings
are currently being validated to confirm both HuR and LFA-1 dependence.

Discussion:
Our results support the hypothesis that monocyte/macrophage β2 integrin
engagement results in modulation of the mRNA-binding protein HuR, resulting in
stabilization of VEGF mRNA. In vitro experiments demonstrate that bone-marrow
derived macrophage LFA-1 engagement results in stabilization of otherwise labile VEGF
mRNA transcripts. HuR-deficient BMDMs lose integrin VEGF mRNA stabilization.
These results are consistent with previous findings by the Bender laboratory which
showed that human peripheral T cell LFA-1 engagement significantly extends the halflives of ARE-containing transcripts, including TNF-α, GM-CSF, and IL-3 (46).
The molecular signaling pathway responsible for transducing the signal between
LFA-1 engagement and HuR nuclear-to-cytoplasmic translocation in BMDMs remains
unknown. This study suggests that p38 is in the pathway. Previous work done in our lab
on peripheral human T cells demonstrates that LFA-1 activates Vav-1 in a PI-3 kinase
dependent manner. Vav-1 is a guanine nucleotide exchange factor (GEF) for Rac-1 and
Rac-2, both members of the Rho family of GTPases. Activation of Vav-1 causes the Rac
molecules to exchange its GDP for GTP, activating Rac and thus its downstream
effectors. Both Vav-1 and Rac activation are required for T cell LFA-1 mediated mRNA
stabilization (Ramgolam, manuscript submitted). We propose that p38 is the critical
downstream Rac effector leading to HuR translocation and labile mRNA stabilization.
Although we assume that the proximal, required signaling molecules are identical in T
cells and macrophages, this may not be correct. For example, macrophages may have
different GEFs, required for GTP loading of Racs. Studies are ongoing in our laboratory
to define any macrophage-specific components of this pathway.

The role of HuR in conferring stability to ARE-bearing transcripts (i.e. VEGF
mRNA) in BMDMs remains to be fully understood. Demonstrating VEGF mRNA
stabilization and HuR translocation after LFA-1 engagement suggests that HuR plays a
role in integrin-induced posttranscriptional regulation of VEGF mRNA. However, to
confirm this, a macrophage-specific HuR knockout mouse was generated by a senior
researcher (Mark Collinge) in our laboratory. This mouse, described in the methods
sections, involves in vivo gene targeting, engineering ―loxP‖ cre recombinase recognition
sites flanking exon 2 of the HuR gene. This mouse was then crossed with a
transgenically engineered mouse expressing cre recombinase under the control of the
Lysozyme M promoter. After several breeding generations, a HuRflox/floxLysMcre mouse
was generated. This mouse, via western blot analysis, was confirmed to be a tissuespecific knockdown. That is, the mouse was partially deficient in HuR in macrophages
and neutrophils, but not in other cell types. However, the knockdown efficiency was
determined to be variable and sometimes incomplete. Analysis of three random
HuRflox/floxLysMcre (KO) mice showed that HuR knockdown varied significantly (from
53-95% knockdown). The variability in knockdown using the lysozyme M promoter has
been previously described (51), with a reported deletion efficiency of 83-98% in mature
macrophages. The variability in our system is significantly greater than that reported by
Clausen et al. As mentioned above, there may be variability in the level of cre
recombinase expression. That is, cre recombinase is under the control of the Lysozyme
M promoter—little is known about the regulation of this promoter. Alternatively, for a
multitude of reasons, there may be inadequate excision of exon 2 at the loxP recognition

sites. Reasons for this are diverse spanning from poor binding (i.e. inaccessible
chromatin structure) to insufficient cre recombinase protein.
In subsequent experiments, BMDMs from HuRflox/floxLysMcre mice were
screened for a minimum HuR knockdown efficiency of 90%. This value was arbitrarily
set to include only our best knockdowns in experimentation. Thus, when repeating the
mRNA stabilization assay using knockout macrophages, we were able to show that
BMDMs with a 90% knockdown of HuR showed a loss of VEGF mRNA stability after
LFA-1engagement. These results confirmed our initial hypothesis that LFA-1-induced
stabilization of VEGF mRNA is HuR-dependent. Interestingly, VEGF mRNA transcripts
from WT non-LFA-1 engaged cells from the previous experiment (Figure 2) decayed to
their half-life by 30 minutes while VEGF mRNA transcripts from KO LFA-1 engaged
cells decayed to their half–life by 60 minutes (Figure 12). That is, with less than 10% of
the original HuR protein expression, there was still a partial stabilizing effect on VEGF
mRNA, yielding a half-life that was twice as long as non-LFA-1 engaged cells.
When corresponding this to the protein level, an interesting result surfaced which
suggested that both basal and stimulated (integrin-activated) VEGF protein expression is
dependent on HuR. We have not investigated the HuR-dependent augmentation of basal
VEGF levels in these cells, which retain HuR in the nucleus in non-activated cells.
Although these findings are focused around LFA-1 engaged VEGF mRNA
stability, the extrapolation could be made to all pro-angiogenic factors containing AREs
in the 3’ UTR region of the mRNA transcript. That is, HuR might stabilize and prolong
the half-lives of several pro-angiogenic transcripts containing AREs. Preliminary results
from the Bender laboratory have shown that BMDM LFA-1 engagement confers both

Matrix Metallopeptidase 9 (MMP9) and Angiopoietin 2 mRNA stability. MMP9
participates in extracellular breakdown during angiogenesis (allowing for endothelial
migration) and tissue remodeling (54). Angiopoietin 2 has been implicated in tube
formation, migration of endothelial cells, vessel sprouting and regression during an
angiogenic response (55). Both possess AREs in their 3’UTR which make them
amenable to stabilization by HuR.
After confirming an essential role for HuR in the posttranscriptional regulation of
the pro-angiogenic cytokines in vitro, we assessed whether these results could be
replicated in vivo. VEGF has been shown to play a critical role in regulating
inflammatory and ischemic angiogenesis in vivo (56). Therefore, the development of a
macrophage-driven model involving inflammatory angiogenesis was implemented.
Polyvinyl Alcohol (PVA) sponges were implanted subcutaneously to induce a chronic
inflammatory process. Two assumptions were made prior to proceeding. Cells
infiltrating the sponges are mostly macrophages that have been LFA-1 engaged and
activated. Secondly, the neovascularization event is driven by macrophages and is VEGF
dependent. Analysis was conducted at 2-4 weeks to assess VEGF levels along with
corresponding vascularity. At 2 weeks, there was a large induction of VEGF mRNA in
the sponges from WT mice compared to that in the sponges from KO mice. This trend
persisted through 4 weeks but was less apparent as the levels of VEGF mRNA
precipitously declined after 2 weeks. The number of macrophages infiltrating the sponge
were assessed and shown to be equal in both the KO and WT mice. This confirms that
the KO mouse did not have a leukocyte recruitment defect. All differences in VEGF
mRNA levels, therefore, were directly attributable to the differential expression and

regulation of the macrophages rather than the number of macrophages present. Finally,
when assessing vascularity via CD31+ staining on paraffin-embedded sections of the
sponge, there appeared to be no difference at 2 weeks, and a modest reduction of blood
vessels in sponges from the KO mouse at 3 and 4 weeks.
Despite significant variation in the level of VEGF mRNA expression, the KO
mouse had a minimally different angiogenic phenotype from the WT mouse. There are
several possible explanations for this. First, the macrophage-specific HuR knockout
mouse yields an incomplete knockdown. It is unclear exactly how much HuR is required
to result in stabilization. At 90% knockdown in our in vitro studies, there were
noticeable differences in VEGF mRNA stability. However, despite 90% knockdown, the
half life of the VEGF mRNA transcript was twice as long (60 minutes) when compared
to non-LFA-1 engaged WT samples (30 minutes) indicating some stabilization. When
screening the KO mice for this particular experiment, blood monocytes were assessed via
FACs analysis and determined to be at least 75% HuR depleted. This lower criterion was
established to account for incomplete staining via the intracellular HuR staining method
currently in place. Assuming such a low threshold during screening of the mice, and
showing in our in vitro studies that less than 10% HuR within a cell has some stabilizing
effect, the mice used for this in vivo study might have sufficient levels of HuR to
differentially stabilize alternative angiogenic transcripts. That is, although there was a
large difference in VEGF mRNA stability, perhaps other ARE-bearing angiogenic
transcripts may have been stabilized in the KO mouse, minimizing the angiogenic
phenotype of this mouse.

Furthermore, in our in vivo model, there may be several non-HuR dependent
angiogenic factors contributing to the angiogenic phenotype, thus masking the
contribution of HuR dependent angiogenic factors. There may also be alternative cell
types, such as fibrocytes that contribute to the angiogenic phenotype in a model of
chronic inflammation. Fibrocytes are connective tissue fibroblast-like cells that circulate
through the peripheral blood (57). After subcutaneous implantation of ―wound
chambers‖ in mice, they are rapidly recruited to the site of inflammation where they
proliferate. In this inflammatory milieu, fibrocytes produce and secrete MMP-9, VEGF,
basic fibroblast growth factor (bFGF), IL-8, and platelet derived growth factor (PDGF)
which together, promote endothelial cell migration, proliferation, and tube formation
(58). These are the same pro-angiogenic transcripts that are produced by macrophages.
In our model, fibrocytes should have normal HuR levels. Thus, these fibrocytes may
mask the macrophage-dependent angiogenic component that was originally in question.
To counter some of these concerns, an alternative model of ischemic angiogenesis
is currently being implemented in the Bender laboratory. This model involves hindlimb
ligation of the femoral artery to induce a stable but severe ischemic hindlimb (59). This
model was implemented under similar assumptions from the sponge implant. That is,
cells infiltrating the ischemic muscle are mostly macrophages that have been LFA-1
engaged and activated. Also, the neovascularization event (at least early) is anticipated to
be driven by macrophages. The obvious difference in this model, however, is the inciting
stimulus to macrophage recruitment. This model will study the macrophage response to
ischemia, rather than chronic inflammation. Secondly, it has been demonstrated that
ischemic tissue-localized macrophages play a significant role in the neovascular

response. A final approach to developing this new model is to assess a variety of proangiogenic, HuR dependent cytokines (in addition to VEGF) that are involved in the
ischemic milieu. This will better help characterize the angiogenic picture before finally
assessing vascularity via CD31+ immunohistochemistry staining.
In addition to establishing a new in vivo model, the nature of the macrophages in
question will have to be better characterized. Several studies have recently described the
plasticity and functional polarization of macrophages (60, 61, 62). Clasically,
macrophage activation by IFN-ϒ, LPS, or TNF-α, is characterized by high capacity to
present antigen, high production of reactive oxygen species, and high production of
interleukin-12 (IL-12) and IL-23 (63). Functionally, they are potent effector cells,
phagocytosing microorganisms, tumor cells, and producing proinflammatory cytokines.
In the spectrum of macrophage polarization, these cells are referred to as M1
macrophages. An ―alternative activation‖, initiated by a variety of alternative cytokines,
produces M2 macrophages. These can be further subdivided based on the inducing
agents: M2a (induced by IL-4, IL-13), M2b (induced by immune complexes and TLR
agonists), and M2c (induced by IL-10 and glucocorticoid hormones) (64). M2
macrophages are characterized by low production of proinflammatory cytokines (IL-1,
TNF-α, and IL-6) and functionally are involved in immunoregulation, tissue remodeling,
and the promotion of angiogenesis. Therefore, the predominant cytokines within an
inflammatory or ischemic milieu have the potential to polarize the macrophage, yielding
very different functional outcomes.
When establishing subsequent in vivo models to assess the role of macrophages, it
becomes critically important to understand the cytokine profile within the inflammatory

or ischemic environment. Furthermore, specific to our HuRflox/floxLysMcre (KO) mouse,
it is important to note if this genotype results in a significant polarization of the
macrophage compared to it WT counterpart. A previous study has confirmed that human
monocytes differentiated with GM-CSM or M-CSF have both M1 and M2 properties
(63). Thus, the macrophages in the in vitro studies do not have a significant functional
polarization and are likely to be homogeneous between WT and KO after a 7-day period
of exposure to M-CSF. In addition to potential baseline genotypic differences, it will be
of great interest to determine whether subsequent β2 integrin engagement confers a
differentiation signal, in part through stabilization of a profile of otherwise labile
transcripts. This may have significant implications on both our in vitro and in vivo model
systems. Assessing the cytokine profile of HuR WT and KO macrophages before and
after integrin engagement may be a reasonable study to address this hypothesis. These in
vitro results may then be extrapolated to better understand the yet unknown cytokine
profile of the hindlimb ischemia or PVA sponge implant model.
As our laboratory moves forward understanding the posttranscriptional regulation
of mRNA transcripts in macrophages, we will continue to identify and characterize novel
transcripts that are affected by β2 integrin engagement in a HuR dependent manner. The
preliminary results for this endeavor have identified 300 genes in BMDMs upregulated
upon engagement to ICAM-1. As for the HuR dependent genes, the findings were much
smaller with only 29 apparent. The number of genes that were co-dependent on LFA-1
and HuR was only 5. Of note, this experiment was conducted prior to screening for HuR
expression levels. As such, retrospective analysis confirmed a knockdown of HuR
samples ranging from 59-96% knockdown, indicating significant variability amongst the

samples. Also, the genes known to be regulated by HuR (positive control genes) did not
emerge from the analysis. Although this brings into question the validity of this
microarray for assessing HuR dependent genes, further validation is warranted and will
provide strong evidence in favor (or disfavor) of the current findings.
Through this study, we have shown that macrophage β2 integrin (LFA-1)
engagement results in stabilization of the angiogenic transcript, VEGF mRNA, and that
macrophage HuR is one of the components for mediating neovascular responses. As we
move forward to alternative models of in vivo angiogenesis assays, we will broaden the
scope of pro-angiogenic factors assessed in order to better characterize the angiogenic
environment. Furthermore, the complex and plastic nature of recruited macrophages
needs to be assessed in the setting of inflammation or ischemia. Our current findings,
applied to our future directions, would provide an even deeper understanding of the posttranscriptional regulatory mechanisms of angiogenesis.
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Figure 1: Phenotype of murine BMDMs. Murine bone marrow derived macrophages
were isolated and cultured as described in the Methods section in RPMI media
supplemented with M-CSF. After 7 days of culture, adherent cells were harvested to
assess the purity of the macrophage population. The samples were analyzed by flow
cytometry and double stained with FITC-conjugated anti-F4/80 antibody and PEconjugated anti-CD11b antibody (both identifying markers of macrophages).
Figure 2: Effect of LFA-1 engagement on VEGF mRNA decay. After 7 days of bone
marrow derived isolation and expansion (see Methods section), cells were harvested,
washed in LFA-1 activation buffer (cation-based solution) and adhered to ICAM-1 or FC
conjugate control plates for 30 minutes before being replaced with RPMI for an
additional 2.5 hours. At 3 hours, a transcriptional inhibitor DRB was added (time 0).
The RNA was harvested at time 0, 30, and 60 minutes for VEGF real-time. VEGF
mRNA levels were normalized to GAPDH mRNA levels. (N = 3, mean +/- SD).
Figure 3: β2 integrin-induced HuR translocation in BMDMs. After 7 days of
proliferation in RPMI/L Cell enriched media, BMDMs were harvested and suspended in
LFA-1 activation buffer (cation-based solution), following which they were plated on
coverslips coated with immobilized recombinant ICAM-1 or FC conjugate control for 45
minutes. Cells were then fixed (4 % paraformaldehyde) and permeabilized (0.1% Triton
X-100). Immunofluorescent analysis was performed with anti-HuR antibody (red) and
the nuclear marker DAPI (blue). Magnification of the images is 1000x. These results are
representative of 4 independent experiments.
Figure 4: β2 integrin-induced p38 MAPK activation in BMDMs. Murine BMDMs
were harvested after 7 days of proliferation and differentiation in RPMI/L Cell enriched
media. Cells were suspended in LFA-1 activation buffer and plated on ICAM-1 coated
plates or control plates for 5, 10, 15, and 25 minutes. Non-adherent cells were aspirated
and adherent cells were collected and lysed at the respective time points. The cell lysates
were immunoblotted for phosphorylated p38 MAPK and total p38. ―No Tx‖ lane
indicates lysates from non-adherent cells (serving as a secondary negative control).
Lanes ―L5‖ to ―L25‖ represent lysates from adherent control samples and lanes ―I5‖ to
―I25‖ represent lysate samples from cells adherent to ICAM-1. Phosphorylated p38 was
normalized to total p38 MAPK. These results are representative of 3 independent
experiments.
Figure 5: Targeting the Elavl1 (Hu antigen R) gene.
Figure 6: HuR levels in macrophage-specific HuR KO cells. BMDMs and splenic
lymphocytes were isolated from HuRflox/flox and HuRflox/floxLysMcre mice. After isolation
of BMDMs, cells underwent a 7 day culture process in RPMI + L cell enriched media.
Lymphocytes were purified from the splenocyte population using a Histopaque gradient.

Purified cells populations were then lysed and immunoblotted for HuR AUF-1 (serving
as a non-gene manipulated RNA binding protein control).
Figure 7: HuR expression in WT and KO BMDMs. Bone marrow derived
macrophages were isolated from 3 HuRflox/flox and 3 HuRflox/floxLysMcre mice from
different littermates. After isolation of BMDMs, cells underwent a 7 day proliferation
and differentiation in RPMI + L cell enriched media. Cells were then harvested, lysed,
and extracts immunoblotted for HuR and actin as a control for normalization.
Figure 8: HuR expression levels from WT and KO BMDMs. Bone marrow derived
macrophages were isolated from 3 HuRflox/flox and 3 HuRflox/floxLysMcre mice from
different littermates. After isolation of BMDMs, cells underwent a 7 day proliferation
and differentiation in RPMI + L cell enriched media. Cells were then harvested, lysed,
and RNA extracted for reverse transcription and real-time PCR for HuR. Data are
displayed as % of mRNA levels of WT controls (e.g. KO 1 HuR mRNA % of WT 1).
Figure 9: FACS analysis of HuR expression in WT and KO macrophages. Murine
bone marrow derived macrophages were isolated and cultured as described in the
Methods section in RPMI media supplemented with M-CSF. After 7 days of culture,
adherent cells were harvested for flow cytometric analysis. The BMDMs from WT and
KO mice were stained with an Alexa-648 conjugated anti-F4/80 antibody and a PEconjugated anti-CD11b antibody. Cells were subsequently permeabilized and stained
with anti-HuR antibody conjugated to a zenon alexa 488 tag or corresponding isotype
control. Cells were first gated on the live population and then gated on the double
positive F4/80, CD11b population to analyze macrophages only. Within this gated
population, HuR expression levels from WT and KO samples stained with anti-HuR or
the isotype control are shown. A table comparing geometric means of the histograms is
shown on the right.
Figure 10: Phenotype of HuR+ cells in the KO population. As in figure 8,
differentiated BMDMS from KO mice were stained with an Alexa-648 conjugated antiF4/80 antibody and a PE-conjugated anti-CD11b antibody. Cells were subsequently
permeabilized and stained with anti-HuR antibody conjugated to a zenon alexa 488 tag or
corresponding isotype control. In order to confirm the presence of HuR in the CD11b+,
F4/80+ cell population, a technique of ―back-gating‖ was used. When gating only the
HuR positive cells from the KO sample (difference between KO HuR and KO isotype
histogram), this subpopulation of cells can be assessed for CD11b, F4/80 macrophage
markers.
Figure 11: HuR FACS analysis in mouse peripheral blood leukocyte subsets.
Peripheral blood was acquired via retrobulbar bleeding from WT and KO mice. RBC
lysis was performed and remaining leukocytes were surface stained with Alexa-648

conjugated anti-F4/80 antibody and a PE-conjugated anti-CD11b antibody. Cells were
subsequently permeabilized and stained with anti-HuR antibody conjugated to a zenon
alexa 488 tag or corresponding isotype control. After live gating, were gated as double
positive (F4/80+, CD11b+) in order to identify macrophages or single positive (F4/80-,
CD11b+) in order to identify granulocytes (and NK cells). HuR expression levels within
these gated populations were then assessed.
Figure 12: Loss of Integrin-induced VEGF mRNA stabilization in HuR KO
BMDMs. After 7 days of bone marrow derived isolation and expansion from WT and
KO mice (see Methods), cells were harvested, washed in LFA-1 activation buffer and
adhered to immobilized recombinant ICAM-1 plates for 30 minutes followed by
replacement with complete media for an additional 2.5 hours.. At 3 hours, DRB was
added (time 0). The RNA from WT and KO BMDMs was harvested at time 0, 30, and
60 minutes for real-time, VEGF RT-PCR. VEGF mRNA levels were normalized to
GAPDH mRNA levels. (N = 2, mean +/- SD).
Figure 13: VEGF protein levels in supernatants recovered from integrin-engaged
WT and KO BMDMs. After 7 days of bone marrow derived isolation and expansion
from WT and KO mice (see Methods), cells were harvested, washed in LFA-1 activation
buffer and adhered to immobilized recombinant ICAM-1 plates or Fc conjugate control
plates for 30 minutes, followed by replacement with complete media for 23 hours. The
supernatant was then collected and VEGF protein levels were determined by ELISA. (N
= 2, mean +/- SD).
Figure 14: VEGF mRNA expression levels from PVA sponge implants. Sterile
polyvinyl alcohol sponges were inserted into the dorsum of WT and KO mice. At
indicated time points (3 days, 1, 2, 3, and 4 weeks), the mice were euthanized and the
sponges were explanted. For RNA isolation, the skin was detached from the sponge.
The sponge was then minced and homongenized using a tissue homogenizer in RLT lysis
buffer. RNA was isolated via a RNeasy kit (Qiagen) followed by reverse transcription,
and analyzed via real-time PCR. Murine VEGF mRNA levels were normalized to
GAPDH mRNA at each time point. Expression levels are illustrated as a fold increase
over the ―3 D KO‖ (three day knockout) sponge VEGF mRNA level. Note: 3 pooled
mice were used to achieve adequate total RNA concentration.
Figure 15: FACS quantification of macrophages in explanted PVA sponges. PVA
sponges were implanted subcutaneously over the dorsum of WT and KO mice. Sponges
were explanted at 2, 3, and 4 weeks post-implantation and cells were extracted via
Collagenase Type I digestion. RBCs were subsequently lysed and remaining cells were
manually counted. Cells were then surface stained with Alexa-648 conjugated anti-F4/80
antibody and a PE-conjugated anti-CD11b antibody. After live gating, cells from 3 and 4

week PVA sponge implants were analyzed for F4/80 plus CD11b positivity (figure on
left). Combining the absolute cell counts and the % of double-positive cells, the total
number of macrophages infiltrating the sponge were calculated (figure on right).
Figure 16: CD31+ microvessels in implanted PVA sponges (4 wks). PVA sponges
were implanted subcutaneously over the dorsum of WT and KO mice. Sponges and
adherent skin were explanted at 2, 3, and 4 weeks post-implantation and fixed overnight
in a formalin-free zinc fixative solution, embedded in paraffin, and sectioned into 5 µm
sections. Immunohistochemistry staining using anti-CD31 antibody was performed
(secondary: biotinylated anti-rat). CD31 positivity is illustrated in the 4 wk wild type
mouse at both low and high magnification.
Figure 17: Neovessel quantification in PVA sponges implanted in macrophage HuR
WT and KO mice. PVA sponges were implanted subcutaneously over the dorsum of
WT and KO mice. Sponges and adherent skin were explanted at 2, 3, and 4 weeks postimplantation and fixed overnight in a formalin-free zinc fixative solution, embedded in
paraffin, and sectioned into 5 µm sections. Immunohistochemistry staining using antiCD31 antibody was performed. CD31 positivity in 2 week and 4 week WT and KO
sponges are illustrated in 17A, as well as in 3 week and 4 week blinded individuals in
17B. All vessels were manually counted by two blinded individuals. 17A represents an
average of CD31+ vessels in 25 fields of view under high magnification, while 17B
represents all the CD31+ vessels present in each sponge. Numbers represent an average
of two counts.
Figure 18: RT-PCR validation of microarray diff score data. Microarray analysis
comparing gene expression levels in BMDMs isolated from HuRflox/flox(WT) and
HuRflox/floxLysMcre (KO) mice, bound or unbound to ICAM-1 was performed using
Illumina’s Beadstudio software program. To analyze the HuR-independent components
of the microarray, the reference group was set to ―WT No Tx‖ (no treatment). The filter,
a simple AND/OR algorithm was set as follows: Branch 1 = KO, diff score >13, KO,
diff score < -13. Branch 2 = KO, p-value < 0.01, WT No Tx, p-value < 0.01. This
analysis resulted in 5924 genes with ~ 300 genes having + Diff scores comparing WT
ICAM bound to the reference group. Within this group of 300, several chemokine genes
had significant induction patterns on ICAM-1. These chemokines were selected for
validation via RT-PCR. Primers were designed for CCL2, CCL3, CCL4, CCL5, and
CCL7. An identical experiment was conducted using BMDMs from a WT and KO
mouse. On the left, the original microarray Diff scores are demonstrated. On the right,
the validated RT-PCR data demonstrates transcript expression levels normalized to
GAPDH.

Table/Figure 19: Integrin and HuR-dependent gene expression levels from WT and
KO macrophages. Microarray analysis comparing gene expression levels in BMDMs
isolated from HuRflox/flox(WT) and HuRflox/floxLysMcre (KO) mice, bound or unbound to
ICAM-1, was performed. To analyze the HuR-dependent components of the microarray,
the reference group was set to ―KO 3‖ (ICAM engaged). The filter, a simple AND/OR
algorithm was set as follows: Branch 1 = WT 3, diff score >13, WT 3, diff score < -13.
Branch 2 = WT 3, p-value < 0.01, KO 3, p-value < 0.01. This analysis resulted in 1045
genes with 29 genes having + Diff scores comparing WT 3 with the reference group, KO
3. Table 1 lists all the genes that show a statistically significant difference between WT 3
(ICAM-bound) and KO 3 (ICAM-bound) groups. Genes are listed by descending dif
scores for WT 3. The ―comments‖ column in the table identifies 5 genes that have both
HuR-dependent and LFA-1 dependent expression patterns. The average signal intensities
of these five genes from the original microarray are illustrated in Figure 19.
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Figure 3 β2 integrin-induced HuR translocation in BMDMs
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Figure 4 β2 integrin-induced p38 MAPK activation in BMDMs
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Figure 5 Targeting the Elavl1 (HuR) gene
Wild-type allele (Chr 8)
Start codon in exon 2

1

B

B

2B

E

3

4

5

6
B - BamHI
E - EcoRI

Targeting
vector in
pEasy Flox
2

Neo
Neomycin deleted
with Cre-mediated
recombination in
ES cells

2

1

2

3

4

5

6

HuRfl allele
HuRD allele following
1
Cre-recombination in vivo:
exon 2 with the start codon is missing

3

4

5

6
Timur Yarovinsky; Adapted from Mark Collinge

Figure 6 HuR levels in macrophage-specific HuR KO cells

Figure courtesy of Mark
Collinge

Figure 7 HuR Expression in WT and KO BMDMs
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Figure 8 HuR mRNA expression levels from WT and KO BMDMs
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Figure 9 FACS analysis of HuR expression in WT and KO macrophages

Figure 10 Phenotype of HuR+ cells in the KO population
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Figure 11 HuR FACS analysis on mouse peripheral blood leukocyte subsets
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Figure 12 Loss of integrin-induced VEGF mRNA stabilization in HuR KO BMDMs
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Figure 13 VEGF protein levels in supernatants recovered from
integrin-engaged WT and KO BMDMs
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Figure 14 VEGF mRNA expression levels from PVA sponge implants
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Figure 15 FACS quantification of macrophages in explanted PVA
sponges
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Figure 16 CD31+ microvessels in implanted PVA sponges (4 wk)
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Figure 18 RT-PCR validation of microarray Diff score data
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Figures 17A, 17B Neovessel quantification in PVA sponges
implanted in macrophage HuR WT and KO mice
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Figure 18 RT-PCR validation of microarray Diff score data
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Figure 18 RT-PCR validation of microarray Diff score data

mRNA Expression
(normalized to WT no Tx)

CCL7 mRNA Expression (BMDM)
160
140
120
100
80
60
40
20
0
WT no Tx KO No Tx WT ICAM KO ICAM

Figure 19 Integrin and HuR-dependent gene expression
levels from WT and KO macrophages

Table: Microarray Transcript Data: ICAM and/or HuR Dependence (Diff score > + 13)

Gene Symbol
Cav1
XIST
EIF2S3X
TAPBP
MSN
LysS
THOC4
GNB1
TFRC
PDIA6
CCNB1
PRDX1
RAC1
GPR84
MS4A6D
KCMF1
SLC39A4
CD276
PPIC
TRP53INP2
LPCAT2
MTCH2
PSMA7
RBPMS
SRPK1
COPZ2
PPAPDC1
PSMG2
EBPL

Gene Name
Caveolin 1
inactive X specific transcripts
eukaryotic translation initiation factor 2, subunit 3, structural
gene X-linked
TAP Binding Protein
Moesin
Lysozyme S
THO complex 4
guanine nucleotide binding protein (G protein), beta 1
transferrin receptor (p90, CD71)
protein disulfide isomerase associated 6
cyclin B1
peroxiredoxin 1
RAS-related C3 botulinum substrate 1
G protein-coupled receptor 84
membrane-spanning 4-domains, subfamily A, member 6D
potassium channel modulatory factor 1
solute carrier family 39 (zinc transporter), member 4
CD276 antigen
peptidyl-prolyl cis-trans isomerase C
transformation related protein 53 inducible nuclear protein 2
lysophosphatidylcholine acyltransferase 2
mitochondrial carrier homolog 2
proteasome (prosome, macropain) subunit, alpha type 7
RNA binding protein gene with multiple splicing
serine/arginine-rich protein specific kinase 1
coatomer protein complex, subunit zeta 2
phosphatidic acid phosphatase type 2 domain containing 1B
proteasome (prosome, macropain) assembly chaperone 2
emopamil binding protein-like

Comments
HuR/LFA-1

HuR/LFA-1
HuR/LFA-1

HuR/LFA-1

HuR/LFA-1

